GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Research & Development

TG Therapeutics (STU:NKB2) Research & Development : €85.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. TG Therapeutics's Research & Development for the three months ended in Mar. 2024 was €30.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €85.9 Mil.

TG Therapeutics Research & Development Historical Data

The historical data trend for TG Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Research & Development Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 138.76 136.37 196.98 118.33 69.87

TG Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.82 25.96 13.82 16.00 30.10

TG Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €85.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics  (STU:NKB2) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TG Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (STU:NKB2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Research & Development
Comparable Companies
MLTX RNA ACAD APGE DYN CLDX DNLI ARVN NTLA ACLX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TGTX:USA NKB2:Germany
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
Website
https://www.tgtherapeutics.com
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines